Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial

Circulation Research

Volumn 120, Issue 2, 2017, Pages 332-340

  Butler, Javed ^a   Epstein, Stephen E ^b   Greene, Stephen J ^c   Quyyumi, Arshed A ^d   Sikora, Sergey ^e   Kim, Raymond J ^c   Anderson, Allen S ^f   Wilcox, Jane E ^f   Tankovich, Nikolai I ^g   Lipinski, Michael J ^b   Ko, Yi An ^h   Margulies, Kenneth B ⁱ   Cole, Robert T ^d   Skopicki, Hal A ^a   Gheorghiade, Mihai ^f  

^a STONY BROOK UNIVERSITY   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CardioCell LLC   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Stemedica Cell Technologies Inc   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cardiomyopathy; clinical trial; heart failure; noni; schemic; stem cells; viable myocardium

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PLACEBO; TROPONIN I;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HOLTER MONITORING; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY; NATURAL KILLER CELL; NONISCHEMIC CARDIOMYOPATHY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; UNITED STATES; ALLOTRANSPLANTATION; BLOOD; CARDIOMYOPATHIES; CLINICAL TRIAL; CONVALESCENCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; CARDIOMYOPATHIES; CROSS-OVER STUDIES; FEMALE; HEALTH STATUS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PILOT PROJECTS; RECOVERY OF FUNCTION; SINGLE-BLIND METHOD; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 85000613472     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.309717     Document Type: Article

References (22)

1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-1133. doi: 10.1016/j.jacc.2013.11.053.
2. Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE. Mechanisms contributing to the progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol. 2015;66:2038-2047. doi: 10.1016/j.jacc.2015.09.010.
3. Gheorghiade M, Larson CJ, Shah SJ, et al. Developing new treatments for heart failure: focus on the heart. Circ Heart Fail. 2016;9:e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727.
4. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113:810-834. doi: 10.1161/CIRCRESAHA.113.300219.
5. Narita T, Suzuki K. Bone marrow-derived mesenchymal stem cells for the treatment of heart failure. Heart Fail Rev. 2015;20:53-68. doi: 10.1007/s10741-014-9435-x.
6. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010;21:1641-1655. doi: 10.1089/hum.2010.156.
7. Vertelov G, Kharazi L, Muralidhar MG, Sanati G, Tankovich T, Kharazi A. High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA. Stem Cell Res Ther. 2013;4:5. doi: 10.1186/scrt153.
8. Bayeva M, Sawicki KT, Butler J, Gheorghiade M, Ardehali H. Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail. 2014;7:680-691. doi: 10.1161/CIRCHEARTFAILURE.113.000912.
9. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A; Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14-21.
10. Barsheshet A, Goldenberg I, Moss AJ, Eldar M, Huang DT, McNitt S, Klein HU, Hall WJ, Brown MW, Goldberger JJ, Goldstein RE, Schuger C, Zareba W, Daubert JP. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADiT-CRT. Eur Heart J. 2011;32:1622-1630. doi: 10.1093/eurheartj/ehq407.
11. Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Díez J, Gheorghiade M. Targeting the heart in heart failure: myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail. 2015;3:661-669. doi: 10.1016/j.jchf.2015.04.011.
12. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453. doi: 10.1056/NEJM200011163432003.
13. Greene SJ, Epstein SE, Kim RJ, Quyyumi AA, Cole RT, Anderson AS, Wilcox JE, Skopicki HA, Sikora S, Verkh L, Tankovich NI, Gheorghiade M, Butler J. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2015. [Epub ahead of print].
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852. doi: 10.1161/CIR.0b013e31829e8807.
15. Little RJA, Rubin DB. Statistical Analysis With Missing Data, 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2002.
16. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The sixminute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996;110:325-332.
17. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993;270:1702-1707.
18. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, Peterson ED, Masoudi FA, Krumholz HM, Havranek EP, Conard MW, Williams RE. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol. 2006;47:752-756.
19. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, doubleblind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10.1016/j. jacc.2009.06.055.
20. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013;10:85-97. doi: 10.1038/nrcardio.2012.181.
21. Greene SJ, Gheorghiade M. Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol. 2014;64:1599-1601. doi: 10.1016/j. jacc.2014.06.1199.
22. Greene SJ, Gheorghiade M. Reply: considerations for drug development for heart failure. J Am Coll Cardiol. 2015;65:1061-1062. doi: 10.1016/j. jacc.2014.11.064.